Neuren receives Rare Pediatric Disease Designation from FDA
Filed with ASX · · 1 page · English
Summary by 6ix AI
This designation may allow Neuren to obtain a priority review voucher if the program is reauthorized and the drug receives marketing authorization. Neuren is focused on developing therapies for serious neurological disorders with limited treatment options, and has previously received similar designations for other conditions.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Neuren Pharmaceuticals Limited on 6ix
Earlier from Neuren Pharmaceuticals
- Fast Track granted by FDA for NNZ-2591 in Pitt Hopkins
- Priority Review Voucher sale proceeds received
- Trofinetide marketing application submitted in Europe
- Neuren announces A$50m on-market share buy-back program
- Q3 2024 update
Later from Neuren Pharmaceuticals
- DAYBUE (trofinetide) 2024 net sales US$348 million
- Appendix 4E and 2024 full year accounts
- 2024 results - A$166m comprehensive income for shareholders
- Neuren receives DAYBUE sales milestone payment of US$50m
- Neuren initiates development of NNZ-2591 to treat HIE
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals